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Ebola virus circulation in Africa: a balance between cli-
nical expression and epidemiological silence.
Résumé : Circulation du virus Ebola en Afrique : équilibre entre expression clinique et silence  
épidémiologique.
Environ trente ans après les premières épidémies, on connaît encore peu de choses sur le virus 
Ebola (EBOV), sa transmission reste indéterminée et son réservoir difficile à identifier. Peu de temps 
après l’épidémie de fièvre Ebola et la découverte du virus en 1976, plusieurs pays, y compris des 
zones écologiques, furent l’objet d’une étude approfondie au début des années 80 afin d’étudier 
la répartition de l'EBOV en Afrique centrale : la République Centrafricaine, le Cameroun, le Tchad, 
le Congo, le Gabon et la Guinée-Equatoriale. Depuis 1992 le test ELISA ainsi que la RT-PCR ont été 
utilisés pour la recherche d’anticorps du virus spécifique et pour la caractérisation de l’ARN virale. Les 
zones d’épidémies, géographiquement très éloignées les unes des autres, laissent supposer que le 
réservoir et le cycle de transmission de l'EBOV sont sans doute étroitement liés à l’écosystème de la 
forêt tropicale, hypothèse confortée par la répartition des anticorps. Les épidémies, peu fréquentes, 
semblent indiquer la présence d’un réservoir animal rare, ou écologiquement isolé ayant peu de con-
tact avec l’homme et les primates non-humains. Cependant, des recherches sérologiques diverses 
ont montré une forte prévalence chez l’homme sans signalement de pathologie. Cela indiquerait 
une circulation des souches pathogènes , non pathogènes, et plus de contacts avec l’homme que 
prévus ; cela pourrait également expliquer, en partie, le silence des quinze années de fièvre Ebola 
entre émergence et ré-émergence du virus, dans le bassin congolais. Aujourd’hui, largement éclairée 
par l’étude des récentes manifestations épidémiques et épizootiques de l'EBOV au Gabon et pays 
avoisinants, l’histoire naturelle de l'EBOV commence à être comprise pour ce qui est des principes 
de l’épizootie chez les primates non-humains ainsi que la chaine de transmission.
Summary:
Nearly thirty years after the first epidemics, Ebola virus (EBOV) remains hardly described, its trans-
mission unclear and its reservoir elusive. Soon after the Ebola fever outbreak and virus discovery 
in 1976 and in order to investigate the distribution of EBOV in Central Africa, several countries 
including a range of ecological zones were investigated in the early 1980s, using extensive survey: 
Central African Republic (CAR), Cameroon, Chad, Congo, Gabon and Equatorial Guinea. Since 
1992, ELISA antibody test along with a RT-PCR have been used to detect specific virus antibodies 
and characterize viral RNA. The widely separated geographic locations of outbreaks have sugges-
ted that the reservoir and the transmission cycle of EBOV are probably closely associated with the 
rain forest ecosystem, what is supported by the distribution of antibodies. The fact that outbreaks 
seldom occur suggests the presence of a rare or ecologically isolated animal reservoir having few 
contacts with humans and non-human primates. However various serological investigations showed 
a high prevalence in humans without any pathology reported. This suggests a circulation of both 
pathogenic and non-pathogenic strains as well as more frequent contacts with man than expected, 
and could partially explain fifteen years of Ebola fever silence between the emergence and re-emer-
gence of Ebola virus in the Congolese basin. Nowadays, largely enlightened by the study of recent 
epizootic and epidemic manifestations of EBOV in Gabon and neighboring countries, EBOV natural 
history starts to be understood as for the fundamentals of epizootic in non-human primates and 
chains of transmission.
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Introduction
Ebola virus (EBOV) infection, causing severe hemorrhagic diseases in human and non-human primates (39, 23), was 
identified for the first time as a deadly epidemic at Nzara in 
Southern Sudan (45) and at Yambuku in Northern Demo-
cratic Republic of Congo (DRC, former Zaire) in 1976 (20). 
Since then, EBOV epidemics have been reported in several 
other Central African countries, Gabon, RC and Uganda 
(figure 1), during two distinct periods with a fifteen years gap 
of silence. EBOV are non-segmented negative-strand RNA 
viruses, classified in the family Filoviridae, together with 
Marburg virus. Genetic and antigenic characteristics of the 
Ebola viral strains isolated allowed to identify four different 
types, named after their geographical origin: Zaire Ebolavi-
rus (EBOV-Z), Sudan Ebolavirus (EBOV-S), Côte-d’Ivoire 
Ebolavirus (EBOV-CI) and Reston Ebolavirus (EBOV-R). 
The high mortality rate, from 50 to 90%, the absence of vac-
cine or treatment and the ignorance of the mechanisms of its 
sporadic emergence make EBOV infections one of the most 
dangerous diseases for humans. Most of the cases resulted 
from inter-human transmission (45, 20) and remained not 
informative about its natural reservoir, potential vector, and 
mode of transmission.
Since the first epidemics, research programs have been conduc-
ted all over Central Africa, in both epidemic (cited previously) 
and non-epidemic countries (Senegal, Guinea, Liberia, Côte-
d’Ivoire, Burkina Faso, Benin, Nigeria, Cameroon, Equatorial 
Guinea, Central African Republic (CAR), Chad, Ethiopia, 
Kenya, Zimbabwe, Botswana, Madagascar and the Philip-
pines), to solve the mysterious unknown of EBOV natural 
transmission and maintenance cycle. These studies focused on 
tracking EBOV scars and identifying vulnerable populations 
and environmental factors of EBOV emergence, in assumed 
endemic areas throughout the tropical rain forest. Domestic 
and wild animals were sampled to find potential hosts, reser-
voirs or vectors of virus. The scope of studies, the evolving 
techniques used as well as the unsuspected results make of 
particular interest the review of more than two decades of 
investigation. Herein, we report this extensive prevalence and 
ecological survey, first in epidemic countries exploring the epi-
demiological silence, then beyond the known places of emer-
gence, with the aim of identifying vulnerable populations, and 
lastly investigating the highly diverse fauna to understand its 
wild transmission cycle.
Ebola virus in epidemic Central African 
countries: regular infections behind 
temporal coincidences of outbreaks
Two periods of coincident outbreaks fifteen years 
apart
In 1976, EBOV was first identified in association with two 
consecutive outbreaks from June to November in southern 
Sudan and in September and October in northeastern DRC, 
causing respectively 284 cases with 53% mortality (45) and 318 
cases with 88% mortality (20). Nzara, the village and cotton 
factory where the first Sudanese Ebola outbreak occurred, lies 
150 km from the Central African Republic (CAR) border, in 
the savannah-forest mosaic domain that covers one third of 
CAR. Less than 150 km south of the Oubangui River, which 
is the natural border between Northern DRC and CAR, are 
the villages of Yambuku and Tandala, in the boucle of Ebola 
River, where first Zairian Ebola infections occurred. Both vil-
lages are part of the large phytogeographical domain of the 
Congolese rain forest, which extensively covers the southern 
part of CAR. DRC was hit again in 1977 by an isolated case 
and southern Sudan in 1979 by a fourth outbreak, causing 
34 cases among five families, with 65% mortality (2). After a 
long silence of more than 15 years, Ebola epidemics occurred 
repeatedly starting in 1994 in two different sub-Saharan Afri-
can countries: Gabon in 1994 (52 cases with 60% mortality) 
and during two periods in 1996 (January to April: 31 cases 
with 68% mortality; and July to January 1997: 59 cases with 
75% mortality) (10, 11, 54) and DRC in 1995 (315 cases with 
81% mortality) (23). In 1994 an ethologist was also infected 
during the autopsy of a wild chimpanzee in Côte-d’Ivoire (25). 
In the 1996-1997 outbreak, a case of Ebola hemorrhagic fever 
was diagnosed in a nurse for the first time in South Africa. The 
patient got infected while being exposed to the blood of an ill 
doctor, who was contaminated in Libreville, Gabon. In 2000-
2001, Uganda recorded the largest epidemic, causing 425 cases 
(mortality rate = 53%) (53). Then in 2001 in Gabon, Ogooué 
Ivindo province, where occurred the three consecutive epide-
mics from 1994 to 1997, was affected by a fourth epidemic (65 
cases with 82% mortality) linked to a following outbreak in 
the neighboring Republic of Congo (RC), at Mbomo and Kéllé 
(59 cases with 75% mortality), (29-31). Later, two epidemics 
reoccurred in RC, in the same area: in 2002-2003 at Yembelen-
goye and Mvoula, with subsequent spread respectively at Kéllé 
and Mbomo (143 cases with 89% mortality); and in 2003-2004 
at Mbandza with subsequent spread respectively at Mbomo 
(35 cases with 83% mortality). The last epidemic was recorded 
in May 2004 in Yambio county, southern Sudan, and caused 
17 cases with 41% mortality. To date 13 Ebola epidemics and 
two isolated cases have been recorded, causing a total of 1848 
cases and 1288 deaths, according to the WHO (54); all of them 
occurred in tropical Africa (figure 2). Cases have never been 
reported in the Philippines from where EBOV-R is originated. 
Identified in October 1989, in Reston (Virginia, USA), in infec-
Figure 1.
Central African countries affected by Ebola outbreaks.
Pays d'Afrique centrale affectés par les épidémies dues au virus Ebola.
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ted cynomolgous monkeys from the Philippines, 
EBOV-R has only been associated with epidemics in 
monkeys (Macaca fascicularis) and asymptomatic ill-
ness in humans, while other EBOV subtypes induce 
hemorrhagic fever in both humans and monkeys, 
with various degrees of pathogenicity (34).
Even if some sporadic cases were probably not 
observed, all of Ebola epidemics have shown both 
temporal and spatial coincidences:
- They emerged during two distinct periods: 3 
between 1976 and 1979 and 10 between 1994 and 
2004. No clinical case was declared between these 
two periods.
- Spatially they all occurred in a tropical African 
ecosystem, located between the latitudes of 5° north 
and 5° south.
Serological watch following epidemics
Starting in 1979, several research programs on Filo-
virus epidemiology have been conducted in Central 
Africa, including extensive serological survey and 
clinical awareness in assumed endemic areas. More 
than 15,000 sera and biological samples have been 
tested for EBOV to identify endemic areas and vul-
nerable populations (table I). Most of the studies 
performed the indirect immunofluorescent anti-
body test (IFA), described by WULFF and LANGE 
(55). IFA was adjusted for EBOV by JOHNSON et 
al. (21), and, since then, has been largely used in 
serological surveys to estimate viral antigens. The 
lack of specificity of IFA tests should be mentioned, regar-
ding the high seropositivity recorded. However IFA tests 
could prove seropositivity in the epidemic areas, first under 
surveillance: DRC (15, 17), Sudan (2), Gabon (16, 10), Uganda 
(41) and RC (12). Extended surveys then revealed that EBOV 
infections still occur while no cases are reported inside as 
well as outside the known distribution of former epidemics. 
During the long silence following the first outbreak series, 
surveillance showed periodic infections without epidemics. 
Between 1981 and 1985, JEZEK et al. investigated the region 
of Tandala in DRC, where the 1977 single case was iden-
tified. Suspect cases were reported by local Public Health 
facilities and tested for EBOV infection by IFA (titer ≥1:64) 
(17). Among them, 18 persons from 14 different localities 
were seropositive, which represented a 1% seropositivity 
related to 137 villagers selected as a control. Following the 
1995 outbreak in Kikwit, DRC, BUSICO et al. investigated 
different populations using ELISA test for the detection of 
EBOV-Z IgG antibodies (8). They found 2.2% prevalence 
among workers (9/414) living in and around the city and a 
greater prevalence, 9.3% (15/161) among villagers in areas not 
affected by the 1995 outbreak, showing higher vulnerability 
in closer proximity to the forests. These findings raised the 
complexity of EBOV outbreak, defying all logic in regard to 
the high case-fatality rate and recurrent infections without 
Figure 2.
Ebola outbreaks in Africa.
Épidémies dues au virus Ebola survenues en Afrique.
1- 1976: Nzara-Maridi, Sudan
2- 1976: Yambuku, Democratic Republic of Congo (DRC, ex-Zaïre)
3- 1979: Nzara, Sudan
4- 1994-1995: Minkebe-Mekouka, Gabon
5- 1995: Kikwit, DRC
6- 1996: Mayibout, Gabon 7- 1996-19
7: Booué, Gabon
8- 2000-2001: Gulu-Masindi,
Uganda 9- 2001-2002: Ekata, Gabon
10- 2001-2002: Mékambo-Mbomo-Kéllé, Republic of Congo (RC)
11- 2002-2003: Kéllé-Mbomo, RC
12- 2003: Mbomo-Mbandza, RC 13- 2004: Yambio, Sudan
year country total % Ebola test* references
  tested prevalence
1961-62 Ethiopia 277 19.8 IFA (>1:16) Z TIGNOR et al., 1993
1977 DRC1 984 4 IFA (>1:64) VAN DER GROEN et al., 1978
1977 Sudan (Maridi) 214 33 IFA VAN DER GROEN et al., 1978
1977 Sudan (Nzara) 218 6.4 IFA VAN DER GROEN et al., 1978
1977 Rhodesia 243 3 IFA VAN DER GROEN et al., 1978
1977 Panama 200 2 IFA VAN DER GROEN et al., 1978
1978 DRC 1096 7 IFA (>1:16) HEYMANN et al., 1980
1978 Liberia 481 6 IFA KNOBLOCH et al., 1982
1979 CAR2 1344 3 IFA SALUZZO et al., 1982
1979 Sudan 23 25 IFA (>1:16)? BARON et al., 1983
1979-82 CAR 1909 4.5 IFA GONZALEZ et al., 1983
1980 Kenya 84 5 IFA SMITH et al., 1982
1980 Gabon 253 7.5 IFA (>1:16) S/Z IVANOFF et al., 1982
1980 Zimbabwe 486 2 IFA (>1:16)? BLACKBURN et al., 1982
1980 Cameroon 1517 9.7 IFA (>1:16)? BOUREE et al., 1983
1981 Zaire 138 5 IFA STANFIELD et al., 1982
1981 Kenya 741 1.4 IFA (>1:16) JOHNSON et al., 1982
1981-82 Liberia 225 13 IFA (>1:16) Z VAN DER WAALS et al., 1986
1981-85 DRC 137 1 IFA (>1:64) S/Z JEZEK et al., 1999
1982-83 Guinea 138 8 IFA (>1:16) Z BOIRO et al., 1987
1983 Ethiopia 250 0 IFA (>1:16) Z TIGNOR et al., 1993
1983 Burkina Faso 992 0 IFA (>1:64) S/Z GONZALEZ unpubl., 1986
1983 Benin 603 0.3 IFA (>1:64) S/Z GONZALEZ unpubl., 1986
1984 CAR 296 2.6 IFA (>1:64) MEUNIER et al., 1987
1984 Kenya 471 10 IFA (>1:16) S/Z JOHNSON et al., 1986
1984 Uganda 132 3 IFA (>1:16) S/Z RHODAIN et al., 1989
1984 Senegal 650 22.9 IFA (>1:64) SALUZZO unpubl., 1987
1984-86 Botswana 154 0 IFA (>1:16) S/Z TESSIER et al., 1987
1985 Gabon 213 9.4 IFA (>1:64) MEUNIER et al., 1987
1985 CAR 659 22 IFA (>1:64) MEUNIER et al., 1987
1985 Cameroon 375 2 IFA (>1:16)? PAIX et al., 1988
1986-87 Nigeria 1677 2 IFA (>1:16) S/Z TOMORI et al., 1989
1987 CAR 4295 21 IFA (>1:16) S/Z JOHNSON et al., 1993
1987 CAR 427 17 IFA (>1:128) S/Z JOHNSON et al., 1993
1987 Chad 334 3.6 IFA (>1:16) S/Z GONZALEZ et al., 1989
1987 Cameroon 1152 7.7 IFA (>1:16) S/Z GONZALEZ et al., 1989
1987 RC3 728 10 IFA (>1:16) S/Z GONZALEZ et al., 1989
1987 Equatorial Guinea  688 16.1 IFA (>1:16) S/Z GONZALEZ et al., 1989
1988 Zimbabwe 486 1.9  BLAKBURN et al., 1992
1988 Madagascar 381 4 IFA (>1:16) S/Z MATHIOT et al., 1989
1989-90 Philippines 186 6 IFA (>1:128) Z/R MIRANDA et al., 1991
1995 CAR  190 13.2 ELISA Z GONZALEZ et al., 2000
1996 Gabon 205 23 ELISA S/Z/R GEORGES et al., 1999
1996 Philippines 231 0.4 ELISA MIRANDA et al., 1999
1. DRC : Democratic Republic of Congo (ex-Zaïre), 2. CAR : Central African Republic, 3. RC : Republic of Congo
* Z: EBOV-Z, S: EBOV-S, CI: EBOV-CI, R: EBOV-R
Prevalence of EBOV infections from human serological data in Africa and Asia, since 1961.
Prévalence d’infections du virus Ebola à partir de données sérologiques en Afrique et en Asie  
depuis 1961.
Table I.
Laboratory diagnosis of Ebola and Marburg hemorrhagic fever.
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diseases, suggesting a circulation of both pathogenic and non-
pathogenic strains.
Learning from primates Ebola infections
Populations of non-human primates have been particularly 
affected by EBOV epidemics. During a two-year epidemic in 
the Taï National Forest (Côte-d’Ivoire) half of the population 
of chimpanzees disappeared (25). Simultaneous epizootic have 
been observed in non-human primates in the area of human 
outbreaks, as for the discovery of at least 64 died gorillas, chim-
panzees and duikers before and during the 2001 human Ebola 
outbreaks in Gabon, in spite of the rapid decomposition of 
carcasses in the tropical forest (31). The number of animals, 
asymptomatic hosts of the virus, in the Ogooué Ivindo region 
is probably much higher. Although non-human primates have 
been a source of EBOV infection for humans, they are not 
designated as a reservoir. The study of the mechanisms of their 
infection could inform on those leading to the transmission 
of EBOV from a natural reservoir to humans. Between 1985 
and 2000, LEROY et al. conducted a first serological survey of 
EBOV in 790 non-human primates, belonging to 20 species, 
in Cameroon, Gabon and RC (31). A 12.9% seroprevalence 
(ELISA) of EBOV-Z IgG antibodies in wild-born chimpan-
zees attest a continuous contact of chimpanzees with EBOV. 
The results support the idea of a wide circulation of EBOV 
and, furthermore, of filoviruses in a large ecotone, the Cen-
tral African rain forests, starting long before the first human 
outbreaks. Localized in a narrow equatorial belt, rain forests 
are characterized by dense vegetation on several strata with an 
inner colder climate. Interactions between species, either plants 
or animals, within rain forests can be interpreted as a symbiotic 
ecosystem, for which human activity (forest opening, logging, 
agriculture or settlement) are particularly harmful. These eco-
logical changes account for the pressure on fauna forcing the 
population into new environment and behavior (movement of 
rain forest fauna, introduction of savannah species) and could 
partially explain multiple contacts between host and virus 
reservoir or vector. Likewise the ecotone forest-savannah in 
the Congolese domain or savannah in Sudan is also an area of 
EBOV epidemics extending the range of EBOV distribution. 
Furthermore the EBOV 12.9% seroprevalence rate found in 
wild-born chimpanzees indicates that, like humans, they can 
recover from EBOV infection or can be infected but remain 
asymptomatic (28, 31). Thus, beyond some eventual cases 
not reported or wrongly diagnosed, the long epidemiological 
silence of Ebola outbreak does not necessarily preclude its 
absence.
Ebola virus scars without reported 
cases: a persistent threat in the Con-
golese rain forest
Considering the ecological context of Ebola epidemics in Sudan and Zaire in 1976, CAR was chosen in 1979 
as country site regarding both cultural and environmental 
similarities. In a collaborative effort between the Institut 
Pasteur, Bangui, the Centers for disease control, the United 
States army medical research institute for infectious diseases, 
at Fort Detrick and, the Organisation de coordination pour 
la lutte contre les grandes endémies en Afrique Centrale, at 
Yaoundé (12, 13, 18, 19), a large serological surveillance was 
conducted from 1979 to 1982 to determine the frequency 
and distribution of seroprevalence against several hemor-
rhagic fevers of viral origin. A preliminary study in eastern 
Central African Republic tested 499 human sera samples by 
IFA and reported 3.4% (17 cases) positive with EBOV-Z 
or EBOV-S antigen and a high antibody titer (≥1:64) with 
3 sera, revealing serological scars of potential past contacts 
with EBOV (42). From a total of 1909 human sera tested 
by IFA (≥1:64) in CAR, 4.5% were positive with EBOV-
Z or EBOV-S (12). ELISA techniques, recommended later 
for their higher sensibility and better specificity, were not 
available for the diagnosis of EBOV infections at this time. 
In order to decrease the specificity of IFA, only sera with a 
high antibody titer (≥1:64 for human and animal sera) were 
ultimately considered as potentially positive for Ebola virus 
reacting antibodies and titrated in an attempt to delineate the 
EBOV endemic area in Central Africa.
From 1985 to 1987, 5,070 randomly selected human sera from 
6 Central African countries (Chad, Cameroon, Central African 
Republic, Equatorial Guinea, Gabon and Republic of Congo) 
were tested by IFA (antibody titer ≥1:64) for EBOV, in the 
frame of a serosurveillance of hemorrhagic fevers (12). Both 
rural and urban areas were investigated, over different ecotones 
from dry savannah to tropical rain forest. 12.40% of sera were 
positive to EBOV-Z or EBOV-S antibodies.
From 1992 to 1995, a deep EBOV-Z antibody serological 
investigation was carried out in Lobaye district, south-west 
of Bangui, where previous EBOV antibody high seropre-
valence was detected (13, 18). Lobaye district is covered by 
both preforest grassland and Congolese rain forest (figures 3 
and 4). The study pygmy camps and non-pygmy villages are 
located in a remote forested area, some along the west bank 
of the Oubangui river, and the others along the north bank of 
the Lobaye river, its major tributary. Three groups of pygmy 
camps (Sangoumbe, Sakoungbou and Mogboto) and village 
group (Gouga villages data combined in results and discus-
sion) were investigated. Pygmies who participated in the study 
belong to the Baka group (or Aka) (figure 4). Despite increased 
contact with the villagers living in the forest, most of the Pyg-
mies from that area have preserved a characteristic semi-noma-
dic lifestyle based on hunting and gathering of spontaneous 
natural resources in the rain forest. Villagers from Gouga 
Figure 3.
Seroprevalence of Ebola virus between 1992 and 1999,  
by ecological zone, in Central African Republic (CAR).
Séroprévalence du virus Ebola en République Centrafricaine (RCA) entre 
1992 et 1999, par zone écologique.
Ndélé
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belong mainly to Mbuti tribe (Bantu locutors) and, the others 
to the Mbanza and Ngbundu tribes (Banda locutors). These 
people practice subsistence farming, hunting, limited trapping 
and fishing activities. Sera were collected in November 1995 
at the beginning of the dry season. The results of EBOV-Z 
antibody seroprevalence analysis were compared with tests on 
sera sampled in other provinces, sharing similar environments: 
Belemboke in December 1992 and November 1994, Nola in 
December 1995 and Bangassou in October 1996 (figure 3). A 
direct ELISA test for immunoglobin G (IgG) detection, as 
described by KSIAZEK (24), was realized at the Institut Pasteur 
of Bangui. Each serum, prepared in solutions at four different 
dilutions (14) was tested against EBOV-Z antigen and control 
antigen. Sera were considered as positive if their titer was grea-
ter than or equal to 1:400 and the sum of the optical density 
of all four dilutions was greater than 1.000. EBOV-Z reacting 
antibodies were detected in each village and camp investigated 
in the Lobaye district (table II), as well as in the compared 
areas, Belemboke, Nola and Bangassou (table III): 5.3% of 
the population investigated was seropositive for EBOV-Z 
IgG antibodies. Although the sample sizes were not always 
sufficient to be statistically significant, some trends were still 
observed. The Pygmy Aka population consistently showed 
higher antibody prevalence against EBOV-Z (13.2%) than 
the non-pygmy villagers (4%). Pygmies living in Belemboke 
presented an increasing EBOV-Z antibody prevalence between 
1992 and 1994 (p=0.003) without clinical manifestation. The 
same sera also tested negatively for IgM antibodies. In the 
non-Pygmy population living in Belemboke, Nola and Ban-
gassou, Seroprevalence in villagers living in spoilt forests in 
Nola and Bangassou was close to those recorded at Kikwit 
between two epidemics, in a similar biotope. Among Pygmy 
populations, seroprevalence was recorded higher in females 
(15.3%) than in males (10.9%) but not statistically significant 
(χ2, p =0.15), while it was significantly higher among the 21-
30 age group (p<0.05). Activities, such as cooking or hunting, 
associated with the preparation of meat in forests, are risk 
factors increasing the exposition to the disease. Another survey 
conducted in 1997 in Lobaye district showed a non-
significant increase of the seroprevalence (p=0.12) of 
the villagers and employees of a logging company, 
compared with the state in 1995. A higher seropre-
valence was noticed for the employees working in 
forests than those working in the logging company 
(unpublished data). These investigations concluded 
on an active circulation of EBOV without any dia-
gnosed cases (wrong diagnoses of Ebola as other 
fevers are not excluded) and the potential association 
between infections and human behavior. However, 
contacts between humans, monkeys and the poten-
tial reservoir remain unknown.
Ultimately, considering the fifteen years of absence 
of epidemics, the apparent extensive distribution and 
high prevalence of EBOV reacting-IFA in human 
sera from Central Africa (including CAR, Gabon, 
Cameroon, Equatorial Guinea, Chad and Republic 
of Congo) and the lack of specificity of the IFA test, 
despite its high sensitivity, new techniques were used 
to test for a second time in 1996, sera previously 
collected before the 1990s and tested at the Insti-
tut Pasteur and USAMRIID by IFA a decade ago. 
Respectively 185 and 296 human sera collected in 
1984 and 1987 within CAR rain forest were tested 
again at the Institut für Virology at Marburg using an 
ELISA Test (EBOV-Z antigen) and two other tests 
of confirmation, WB and/or IFAT. No significant difference 
(p>0.01) of EBOV-Z antibody prevalence was found between 
the IFA test performed a decade ago (6.4%) and the tests done 
in 1996 (6.2%). Sera, positive first and negative the second time, 
showed a decrease of antibody while the ones negative first 
and positive later can be the consequence of the cut off of > 
128 or the antigenicity of the strains used in the upgraded test. 
Such findings confirmed the presence of EBOV antibodies in 
CAR human populations ten years ago suggesting that Lobaye 
populations have been in contact with an EBOV or an EBOV-
like antigen since that time. Every serum was also tested by 
ELISA against the EBOV-R antigen (district from the African 
strain and from a Philippine origin) and was negative. EBOV-
infected patients showed a rapid decrease of IFA antibodies 
30 months after onset, while ELISA antibodies remained at 
Figure 4.
Study area in the CAR Lobaye district.
Détail du département de Lobaye en RCA.
village ethnic group male* female* total*
Gouga Bantus 0/26 (0) 2/24 (8.33) 2/50 (4.0)
Sangoumbe Pygmy 2/23 (8.7) 4/28 (14.3) 6/51 (11.8)
Sakoungbou Pygmy 4/24 (16.7) 4/24 (16.7) 8/48 (16.7)
Mogboto Pygmy 4/45 (8.9) 7/46 (15.2) 11/91 (12.1)
total  10/118 (8.5) 17/122 (13.9) 27/240 (11.2)
* positive/total tested (%)
Table II.
EBOV antibody prevalence (IgG, ELISA≥1:400), by ethnic group and sex in 
Lobaye District, Central African Republic, 1995.
Prévalence d’anticorps du virus Ebola (IgG, ELISA ≥ 1:400), selon l’ethnie et 
le sexe dans le département de Lobaye, République Centrafricaine, 1995.
location Pygmies* villagers*
Belemboke CAR, 1992 7/361 (1.9) -
Belemboke CAR, 1994 16/132 (12.1) 3/99 (3.1)
Bangassou CAR, 1995 - 8/226 (3.6)
Nola CAR, 1995 - 10/278 (3.6)
Lobaye CAR (Batalimo, 1997) - 21/205 (10.2)
Gordil CAR, 1998 - 0/29 (0)
Kikwit RDC, 1990 - 5/181 (2.8)
Ngoïla Cameroon, 1998 - 0/21 (0)
* positive/total tested (%)
Table III.
EBOV antibody prevalence (IgG, ELISA≥1:400) in other investigated areas.
Prévalence d’anticorps du virus Ebola (IgG, ELISA ≥1:400) dans les autres  
régions d’enquête.
Laboratory diagnosis of Ebola and Marburg hemorrhagic fever.
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a relatively high titer (Bernard LE GUENNO, pers. comm.). 
Because all of the positive sera, in the present study, reacted by 
both ELISA and IFA tests, it is reasonable to infer that some 
human populations of CAR rain forest were exposed for a long 
period of time to an active EBOV circulation.
Results provide some geographic indications about the poten-
tial location of the chain of transmission, occurring either in 
epidemic or non-epidemic countries. EBOV circulation in 
the Congolese rain forest constitutes a considerable threat 
on local populations, strengthening the need of an effective 
early warning system to detect precursor signs of potential 
outbreak, a quest for which the knowledge of the reservoir 
and vector is a key.
Ebola virus natural transmission: an 
elusive reservoir and vector
Following the first epidemics, animals in closest contact to humans were trapped around the outbreak areas and 
unsuccessfully tested for the identification of any potential 
reservoir species. In Yambuku area (DRC), JOHNSON KM 
inoculated 818 bedbugs, 15 mosquitoes, 123 rodents, eight 
squirrels, seven bats, ten domestic pigs, six monkeys, two dui-
kers and one cow into Vero cell cultures, without succeeding 
in recovering EBOV (20). At the beginning of 1977, in Nzara 
province, ARATA and JOHNSON B. also failed in identifying 
EBOV from 501 specimens of the most common mammalian 
species, including in particular 309 rodents and 178 bats (1).
In 1979, two years after EBOV-Z infected an isolated case at 
Tandala, in DRC, BREMAN et al. collected in DRC and Came-
roon 1664 animals, including 463 bats, 137 squirrels, 514 other 
rodents and 267 primates (7). They were tested, one more time 
unsuccessfully, by IFA, and Vero cells cultures for antibody 
detection and virus isolation, recognizing the lack of specificity 
of serological tests.
A permanent «watch» effectively started in 1979 at the edges 
of the CAR forest, involving a multidisciplinary approach of 
the biodiversity of small terrestrial mammals (13). Among 
1331 animals from different species, tested for EBOV anti-
body seroprevalence by IFA (≥1:64), 17.3% of dogs, 16.3% 
of domesticated guinea pigs and 4.5 to 7.7% of Mastomys 
were positive with EBOV-Z or EBOV-S (table IV). These 
findings were not conclusive by that time regarding the IFA 
lack of specificity.
In 1995, following the Kikwit epidemic in DRC, LEIRS et al. 
tested unsuccessfully 3066 vertebrates, including 1914 rodents, 
for EBOV-Z IgG antibodies by ELISA and virus isolation 
(26). A similar investigation was conducted by REITER et al. 
on 27,843 arthropods, most of which were 15118 mosquitoes 
and 6538 bedbugs (40). All ELISA tests, as well as attempts of 
viral isolation, were negative.
In 1996-1997, FORMENTY et al. could find EBOV-CI anti-
bodies, using ELISA in a monkey species, Colobus badius, 
among 1650 vertebrates collected in Taï forest (9). Unfortu-
nately EBOV-CI could not be isolated.
In 1999 and 2000, MORVAN et al. tested 223 animals (162 
rodents, 24 shrews, 32 birds and 5 primates) for IgM and 
IgG EBOV antibodies by ELISA. All the specimens were 
negative to EBOV IgM antibody. Only one rodent, Praomys 
sp. (from 41 trapped), and one shrew, Sylvisorex ollula (10 
trapped), were positive for IgG antibodies. Then molecular 
techniques (RT-PCR) were used on 947 animals to detect 
EBOV glycoprotein or polymerase gene sequences in RNA 
extracts of the organs (37). Trapped between 1994 and 1999, 
these animals include essentially small mammals: 98%, but 
also 16 birds and 2 reptiles. Seven specimens belonging to two 
genera of rodents (Muridae: Mus setulosus, Praomys sp1 and 
Praomys sp2) and one species of shrew (Soricidae: Sylvisorex 
ollula) were positive. Neither live virus nor virus antigen was 
detected in any organ sample. However RNA and DNA were 
extracted from positive organs and RNA sequences encoding 
fragments of EBOV glycoprotein were amplified (36). Direct 
sequencing of amplicons identified the virus as being of the 
EBOV-Z subtype. Virus-like nucleocapsids were observed 
by electron microscopy in the cytoplasm of the spleen cells of 
one animal. These species are common in the study area and 
share ecosystems bordering forests. These results suggested 
that a common small mammal living in peripheral forest areas 
has been in contact with EBOV and attested the persistence of 
EBOV RNA and DNA in the organs of animals.
Conclusion
Since the disease recognition and the Ebola virus isolated and characterized, serological scars have been observed, 
beyond the places of known outbreaks, throughout Central 
  habitat* total tested % EBOV positive 
    (IFA)
shrew  F 5   0
rodents  709 
 Arvicanthis spp. S 98   9.2
 Mastomys spp. F 91   7.7
 Mastomys spp. S 265   4.5
 Mus spp. F 54   1.8
 Praomys spp. F 195   0
 Praomys spp. S 2   0
 Taterillus spp. S 4   0
other mammals  617 
 cattle F 98   0
 cattle S 20 10.0
 chicken S 131 10.0
 dog F 133 17.3
 dog S 29 34.5
 donkey S 13 23.1
 goat F 21   0
 goat S 75   0
 pig F 80 16.3
 sheep S 17   0
Total   1331
*F = forest, S = savannah
Table IV.
Animals collected in Central African Republic from 1979 to1983 and  
tested for EBOV antibody prevalence (IFA>1:128).
Animaux recueillis en République de Centrafricaine de 1979 à 1983 et ayant 
subi un dépistage d’anticorps du virus Ebola (IFA>1 :128).
Figure 5.
Pygmies populations of Central Africa.
Populations pygmées d'Afrique centrale.
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Africa. Previous observations and studies suggested that 
unknown Filovirus with variable pathogenicity may exist in 
different parts of the World (3). EBOV strain distribution in 
Africa appears limited to a distinct ecosystem geographically 
associated with the rain forest belt. Epidemics seem to be 
related to the behavior of human and non-human primates 
more than a spontaneous circulation of a highly pathogenic 
strain. The Ebola strain from the Taï forest of Côte-d’Ivoire 
has been found in the same ecological zone as its most closely 
genetically-related Ebola-Zaire strain (44). Such divergence 
between the two strains and their association within the 
same forested domain can account for their common ori-
gin, since the Ivorian forested massif was at one time part of 
the Congolese rain forest and became separated during the 
last glaciations (16,000 years before present). By analyzing 
sequences of Marburg and Ebola viruses, SUZUKI and GOJO-
BORI estimated the divergence time between the two viruses 
to be more than several thousands years ago (47). Molecular 
analysis is and will be the key for clarifying the remaining 
Ebola mysteries.
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